Velichka Pavlova, Katya Uzunova, Elena Filipova, Krassimir Kalinov, Toni Vekov
Background: The outbreak of coronavirus disease 2019 (COVID-19) originating from Wuhan, Hubei Province, China at the end of 2019 led to dramatic changes in the healthcare and socioeconomic sectors across the globe. The aim of this meta-analysis was to assess whether favipiravir is a safe and effective option for treatment of COVID-19 patients compared with standard of care (SOC) and/or other applied medicines.
Methods: Data bases were searched up to 31st May 2021 for studies that compare the efficacy and safety of favipiravir and SOC or other relevant therapy in COVID-19 patients. Search results were assessed for relevance on the basis of the following inclusion criteria and relevant results were subjected to a quality estimation using the EPHPP Quality assessment tool.
Results: A total of 10 articles with hospitalized patients and outpatients (n=1016) met our inclusion criteria. Pooled RR 1.24 (95% CI 1.08-1.43, n=5) showed clinical improvement by Day 7 and Day 14 (pooled RR 1.18 (95% CI 1.01-1.37, n=5) and favipiravir was associated with 24% and 18% better outcome compared to other treatment, respectively. Viral clearance by Day 7 and Day 14 with favipiravir was comparable to other treatments (RR 1.1; 95% CI 0.92-1.35, n=5) and (RR 1.07, 95% CI 0.88-1.29, n=5). Safety profile of favipiravir was comparable to that of other treatments (RR 1.21; 95% CI 0.88-1.67) and SEA including death were comparable between treatments (RR 0.64, 95% CI 0.15-2.68, n=4 studies). No correlation between incidence of SEA and treatment option was identified.
Conclusion: There is a significant difference in the clinical improvement detected on Days 7 and 14 in favour of favipiravir. Viral clearance at Days 7 and 14 is comparable between treatments with neither being associated with significantly better outcomes. The safety profiles of favipiravir and SOC regarding SAE show no statistically significant differences.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu